Good candidates for GLP-1 weight loss injections are typically adults with a body mass index (BMI) of 30 or higher, which classifies them as obese
Lawsuit filed against makers of Ozempic, Mounjaro over claims of 'gastrointestinal side effects' A new lawsuit claims the manufacturers of drugs used for weight loss, including Ozempic and Mounjaro, do not adequately warn consumers about the risk of an alleged side effect of the drugs
Keep your pen visible
In more than 50 warning letters sent last week and published on Tuesday, the FDA took these health providers and companies to task for false and misleading claims about the compounded products they market
These shifts vary from slight thinning to a collapsed look with additional wrinkling, occurring in an estimated 5 to 10 percent of patients
The SELECT trial demonstrated that semaglutide provided cardiovascular benefits even when added to background statin therapy, suggesting complementary rather than redundant mechanisms of action